According to Vice President JD Vance, the Trump administration’s approach to border security is directly responsible for reducing drug-related fatalities and keeping narcotics out of Maine.
During an August 24 speech at Brewer, Maine defense contractor Compotech, Vance highlighted recent statistics, stating, “Last year in 2025, did you know that overdoses in the state of Maine were down by 20%, and already in 2026 they’re down by another 17%? We sealed the border, and that’s what happened, my friends, and that’s why we did it.”
While he didn’t explicitly restrict his figures to fatal incidents, he later referenced the loss of life, mentioning that “tens of thousands of Mainers died from fentanyl overdoses by that poison.”
That particular figure was vastly overstated, given that Maine’s annual death toll from overdoses is measured in the hundreds rather than tens of thousands.
Even so, his claim that fatal overdoses have decreased in the state is accurate. This prompted an investigation into whether his assessment of the root cause holds up to scrutiny.
When asked for evidence backing the vice president’s assertions, his office pointed toward ongoing White House initiatives aimed at dismantling fentanyl distribution networks and lowering mortality rates.
However, the downward trend in Maine’s fatal overdoses actually began prior to the current administration taking office, and specialists in drug policy reject the idea that federal border enforcement was the driving force.
Jonathan P. Caulkins, a drug policy researcher at Carnegie Mellon University, noted that the borders were not literally rendered impenetrable to the drug, pointing out that substances are clearly still crossing over or the death toll would be zero.
The Downward Trend Preceded the Second Trump Administration
The vast majority of illicit fentanyl entering the United States originates in Mexico, manufactured using precursor chemicals sourced from China.
Historically, these drugs have primarily moved through official southern border crossings, with fiscal year 2024 data showing that U.S. citizens accounted for the vast majority of those caught smuggling them.
Following two decades of rising fatalities, federal authorities announced in January that overall overdose deaths fell by 21.4% between 2024 and 2025. Roughly a month into the new administration, the Centers for Disease Control and Prevention attributed the reduction to a combination of factors. These included wider availability of the overdose reversal medication naloxone, improved treatment accessibility, shifts in the illegal drug market, and the post-pandemic revival of public health and prevention programs.
This decline was reflected in most states, including Maine.
State and University of Maine records show there were 391 fatal overdoses in the state during 2025, marking an approximate 20% drop from the previous year. During the opening months of 2026, deaths fell another 9.5% compared to the same timeframe in 2025, with fentanyl—frequently mixed with other substances—remaining the primary drug involved.
Vance omitted the fact that these improvements began during the Biden administration, during which annual fatalities had already been falling. Specifically, deaths dropped 19% in 2024 compared to 2023, which itself was 16% lower than the figures recorded in 2022.
Marcella Sorg, a medical and forensic anthropologist at the University of Maine whose research supports the state’s opioid response, explained that the data points to multiple intertwined variables rather than a single cause like border closures.
Local authorities also credit aggressive state-level investments in recovery and treatment programs. Since August 2019, Gov. Janet Mills’ administration has facilitated the distribution of over 870,000 doses of naloxone while funding behavioral health professionals and recovery support systems across environments ranging from workplaces to correctional facilities.
Additionally, Maine has implemented legislative measures designed to curb addiction, such as strict opioid prescribing regulations and protections encouraging individuals to seek medical help during an overdose emergency.
Examining the Administration’s Evidence
In July, the administration pointed to the 2024–2025 drop in overdoses as proof of its strategy, highlighting actions such as labeling cartels as terrorist organizations and enacting the bipartisan HALT Fentanyl Act, which permanently classified fentanyl-related substances as Schedule 1 drugs to impose stiffer penalties.
Officials also cited maritime interdiction efforts, though previous claims regarding dramatic drops in sea-based drug traffic lacked substantiated proof linking intercepted vessels to narcotics.
When reviewed by independent addiction policy experts, the administration’s arguments found limited consensus.
Regina LaBelle, a professor at Georgetown University, noted the difficulty of isolating specific policy drivers, stating that the reduction is just as easily attributed to expanded access to treatment in prisons and jails or broader distribution of naloxone.
Peter Reuter, a professor of public policy and criminology at the University of Maryland, stated there is no proof tying the administration’s specific actions to the decrease in deaths. He suggested the most plausible intervention might be the elimination of the de minimis customs exemption—a loophole that previously allowed small foreign packages valued under $800 to bypass certain tariffs—though he noted that studying its direct impact on fentanyl supplies remains methodologically difficult.
Caulkins added that verifying a direct link is challenging because there is no control group to show what would have happened otherwise. In a January paper published in Science, Caulkins and Reuter discussed how fentanyl availability dropped in the U.S. and Canada starting in 2023, largely due to China cracking down on precursor chemical manufacturers following pressure from the Biden administration.
While acknowledging this is a hypothesis, Caulkins noted that the prolonged tightness in the supply market suggests various government actions by the U.S., Mexico, and Canada likely played some role, making it plausible that Vance’s cited measures contributed.
Reuter previously observed that Drug Enforcement Administration data showed a drop in the purity of seized fentanyl around 2023, which aligns with the initial decline in overdose numbers and likely reflects shifts in the precursor supply chain.
Furthermore, in an August analysis for the Brookings Institution, Reuter and a co-author concluded that the reduction stems from a combination of supply-side disruptions, changes in consumer behavior, and the ongoing work of harm-reduction organizations, without mentioning border policy as a primary catalyst.
Conclusion
Vance attributed the decrease in Maine’s drug overdoses directly to sealing the border.
While Maine has indeed experienced a decline—with 2025 fatalities dropping roughly 20% compared to the previous year—this downward trajectory began under the prior administration.
Public health experts and federal health agencies attribute the broader decline to a multitude of factors, including shifts in the illicit drug market, increased availability of treatment, and expanded use of reversal medications.
Because researchers have found no evidence linking the current administration’s border policies to the drop in Maine’s overdose deaths, the claim is rated False.
Staff Writer Madison Czopek contributed to this report.
RELATED: What’s driving down US overdose deaths? Experts cite drug supply changes, increased naloxone